


**MAP2K2****Mouse monoclonal Antibody****#53820****Catalog Number:** 53820**Amount:** 100µg/100µl**Swiss-Prot No. :** P36507**Form of Antibody:** Purified mouse monoclonal in buffer containing 0.1M Tris-Glycine (pH 7.4, 150 mM NaCl) with 0.2% sodium azide, 50% glycerol**Storage/Stability:** Store at -20°C/1 year**Immunogen:** Purified recombinant human MAP2K2 protein fragments expressed in E.coli**Purification:** affinity-chromatography**Specificity/Sensitivity:** This antibody detects endogenous levels of MAP2K2 and does not cross-react with related proteins**Reactivity:** Human, Mouse, Rat**Applications:** Predicted MW: 44kd WB: 1:500-2000 ICC: 1:200-1000

Western blot analysis using MAP2K2 mouse mAb against PC-12 (1), Jurkat (2), HeLa (3) and NIH/3T3 (4) cell lysate

Background:

MAP2K2, also called MEK2, it is a dual specificity protein kinase that belongs to the MAP kinase kinase family. This kinase is known to play a critical role in mitogen growth factor signal transduction. It phosphorylates and thus activates MAPK1/ERK2 and MAPK2/ERK3. The activation of this kinase itself is dependent on the Ser/Thr phosphorylation by MAP kinase kinase kinases. Mutations in this gene cause cardiofaciocutaneous syndrome (CFC syndrome), a disease characterized by heart defects, mental retardation, and distinctive facial features similar to those found in Noonan syndrome.